A Miracle in Plain Sight: Trump Lowers Drug Prices and Brings Industry Home

When Leadership Delivers: Trump Makes the Impossible Possible on Drug Prices

By John DiMauro

247TrumpNews.com

What is unfolding in the pharmaceutical sector right now may ultimately be remembered as the most important achievement of President Donald Trump’s administration. For decades, Americans were told that lower drug prices, domestic manufacturing, and continued medical innovation could not coexist. That myth has now been shattered.

By bringing industry and government together with firm, results-driven leadership, Donald Trump has done what no president before him ever could: make drugs cheaper for Americans while rebuilding the nation’s pharmaceutical backbone at home.

“We Didn’t Think This Was Possible”

Perhaps the most telling moment came not from a press release, but from the people closest to the negotiations themselves.

Robert F. Kennedy Jr., speaking publicly as these announcements unfolded, admitted that even he did not believe results of this magnitude were achievable. Kennedy said that he and Dr. Oz never thought they would see this happen — calling what has been accomplished “a miracle.”

Coming from a lifelong reform advocate who has battled entrenched pharmaceutical power for decades, the admission was striking. What Washington insisted could not be done was suddenly happening in real time.

A Cascade of Breakthroughs

One announcement after another has confirmed the scale of this transformation.

Bristol Myers Squibb agreed to provide Eliquis, a critical blood thinner, free to Medicaid recipients, saving taxpayers billions while delivering immediate relief to low-income Americans.

Genentech announced it will sell its flu medication direct to patients for just $50, a $70 reduction, while committing $50 billion in new pharmaceutical manufacturing in North Carolina. These are not symbolic gestures. These are structural changes with immediate impact.

Innovation Without Exploitation

The breakthroughs extend beyond pricing.

Gilead Sciences is launching a twice-yearly HIV treatment that has demonstrated extraordinary effectiveness in suppressing the virus and preventing transmission. By replacing daily dosing with just two injections per year, this innovation represents a leap forward in patient adherence and public health — proof that affordability and innovation can advance together.

Manufacturing Comes Home

Now comes what may be the most consequential announcement of all.

Novartis has committed to building nine new pharmaceutical facilities across the United States, including major expansion in North Carolina. This investment will create thousands of high-quality jobs, strengthen domestic drug supply chains, and ensure higher standards and better oversight for critical medicines.

At the same time, GlaxoSmithKline announced steep discounts on its COPD medications, the donation of inhalers at little to no cost, and a $30 billion investment in American manufacturing. Hundreds of billions of dollars are now flowing back into U.S. pharmaceutical production — shutting China out of America’s drug supply chain and restoring national resilience.

A Defining Moment in Leadership

Perhaps the most remarkable signal of how historic this moment truly is comes from the pharmaceutical CEOs themselves. Executives who once resisted reform are now publicly thanking President Trump for his leadership.

They acknowledge what Washington long refused to admit: the system was broken, and only direct negotiation — not endless regulation — could fix it.

When industry and government work together for the good of the common people, anything is possible.

Lower drug prices. Better access. American manufacturing. Stronger national security.

What was once dismissed as impossible has now happened — and history may well record this moment as the turning point when America finally took back control of its healthcare future.